Market overview
The global peptide therapeutics market is worth USD 110 bn in 2026 and is forecast to reach USD 342 bn by 2036, growing at a 12.0% CAGR. United States is the largest country market and Diabetes and obesity is the largest by therapeutic area segment.
| Scope | Medicines whose active ingredient is a synthetic or recombinant peptide, including GLP-1 agonists, GnRH analogues, somatostatin analogues and other therapeutic peptides, excluding insulin. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 95.0 bn |
| Value 2026 | USD 110 bn |
| Value 2036 | USD 342 bn |
| CAGR 2026-2036 | 12.0% |
| Volume 2026 | 533 million treatment packs |
| Volume 2036 | 2,025 million treatment packs |
| Average price 2026 | USD 207 per treatment pack |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Peptide Therapeutics market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 110 bn |
| 2027 | USD 123 bn |
| 2028 | USD 138 bn |
| 2029 | USD 155 bn |
| 2030 | USD 173 bn |
| 2031 | USD 194 bn |
| 2032 | USD 218 bn |
| 2033 | USD 244 bn |
| 2034 | USD 273 bn |
| 2035 | USD 306 bn |
| 2036 | USD 342 bn |
Peptide Therapeutics market segmentation
By therapeutic area
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Diabetes and obesity | 70.0% | 76.3% | USD 77.1 bn | 13.0% |
| Oncology | 9.0% | 6.8% | USD 9.9 bn | 8.9% |
| Endocrine and rare disease | 11.0% | 10.0% | USD 12.1 bn | 10.9% |
| Other areas | 10.0% | 6.9% | USD 11.0 bn | 7.9% |
By route
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Subcutaneous injection | 70.0% | 69.5% | USD 77.1 bn | 11.9% |
| Intravenous and other injection | 18.0% | 14.9% | USD 19.8 bn | 9.9% |
| Oral | 12.0% | 15.5% | USD 13.2 bn | 14.9% |
By peptide origin
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Synthetic peptides | 62.0% | 60.0% | USD 68.3 bn | 11.6% |
| Recombinant peptides | 28.0% | 29.0% | USD 30.9 bn | 12.4% |
| Natural-source peptides | 10.0% | 11.0% | USD 11.0 bn | 13.1% |
By brand status
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Branded peptides | 72.0% | 66.0% | USD 79.3 bn | 11.0% |
| Authorized and follow-on peptides | 14.0% | 16.0% | USD 15.4 bn | 13.5% |
| Generic peptides | 14.0% | 18.0% | USD 15.4 bn | 14.8% |
By synthesis method
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Solid-phase synthesis | 58.0% | 54.0% | USD 63.9 bn | 11.2% |
| Liquid-phase synthesis | 18.0% | 17.0% | USD 19.8 bn | 11.4% |
| Hybrid and recombinant methods | 24.0% | 29.0% | USD 26.4 bn | 14.1% |
Top 25 countries for peptide therapeutics by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 88.5% of 2026 revenue and the 25 countries below together hold 96.8%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 61.7 bn | 56.0% | USD 186 bn | 11.7% |
| 2 | China | USD 7.7 bn | 7.0% | USD 35.9 bn | 16.6% |
| 3 | Germany | USD 5.5 bn | 5.0% | USD 15.1 bn | 10.6% |
| 4 | Japan | USD 5.5 bn | 5.0% | USD 13.7 bn | 9.5% |
| 5 | United Kingdom | USD 3.9 bn | 3.5% | USD 11.6 bn | 11.7% |
| 6 | France | USD 3.3 bn | 3.0% | USD 8.6 bn | 10.0% |
| 7 | Italy | USD 2.8 bn | 2.5% | USD 7.2 bn | 10.1% |
| 8 | Canada | USD 2.8 bn | 2.5% | USD 8.2 bn | 11.5% |
| 9 | Brazil | USD 2.2 bn | 2.0% | USD 7.9 bn | 13.6% |
| 10 | Spain | USD 2.2 bn | 2.0% | USD 6.2 bn | 10.8% |
| 11 | Switzerland | USD 1.3 bn | 1.2% | USD 4.3 bn | 12.7% |
| 12 | Australia | USD 1.1 bn | 1.0% | USD 3.7 bn | 12.6% |
| 13 | South Korea | USD 1.1 bn | 1.0% | USD 3.5 bn | 12.7% |
| 14 | Netherlands | USD 959 mn | 0.9% | USD 3.2 bn | 12.8% |
| 15 | India | USD 782 mn | 0.7% | USD 2.6 bn | 12.6% |
| 16 | Mexico | USD 650 mn | 0.6% | USD 2.2 bn | 12.7% |
| 17 | Belgium | USD 606 mn | 0.6% | USD 2.0 bn | 12.8% |
| 18 | Sweden | USD 507 mn | 0.5% | USD 1.7 bn | 12.7% |
| 19 | Denmark | USD 430 mn | 0.4% | USD 1.4 bn | 12.6% |
| 20 | Turkey | USD 375 mn | 0.3% | USD 1.2 bn | 12.6% |
| 21 | Poland | USD 353 mn | 0.3% | USD 1.2 bn | 12.7% |
| 22 | Saudi Arabia | USD 298 mn | 0.3% | USD 958 mn | 12.4% |
| 23 | Israel | USD 242 mn | 0.2% | USD 821 mn | 13.0% |
| 24 | Austria | USD 209 mn | 0.2% | USD 719 mn | 13.1% |
| 25 | Argentina | USD 198 mn | 0.2% | USD 650 mn | 12.6% |
| Rest of world | USD 3.6 bn | 3.2% | USD 12.0 bn | 12.9% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Novo Nordisk
- Eli Lilly
- Sanofi
- Takeda
- AstraZeneca
- Novartis
Group 2: Regional and specialist players
- Ipsen
- Ferring
- Teva
- Hikma
- Amgen
- Viatris
- Ironwood Pharmaceuticals
- Dr. Reddy's Laboratories
Group 3: Emerging and niche players
- Zealand Pharma
- Hanmi Pharmaceutical
- Rhythm Pharmaceuticals
- Palatin Technologies
- Amphastar Pharmaceuticals
- Biocon
- Gan and Lee Pharmaceuticals
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the peptide therapeutics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 12.0% is calculated from the resulting values.
The market is divided by therapeutic area, by route, by peptide origin, by brand status, by synthesis method. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the peptide therapeutics market?
The global peptide therapeutics market is estimated at USD 95.0 bn in 2025 and USD 110 bn in 2026.
How fast will the peptide therapeutics market grow?
It is forecast to reach USD 342 bn by 2036, a compound annual growth rate of 12.0% from 2026, an increase of USD 232 bn.
Which country is the largest market for peptide therapeutics?
United States is the largest market by revenue at USD 61.7 bn in 2026, 56.0% of the global total. The three largest countries together hold 68.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 16.6% a year from 2026 to 2036.
Which peptide therapeutics segment is largest?
In the by therapeutic area split, Diabetes and obesity is the largest segment with 70.0% of 2026 revenue.
Who are the leading peptide therapeutics companies?
Global leaders include Novo Nordisk, Eli Lilly, Sanofi, Takeda.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- In Vitro DiagnosticsUSD 108 bn · 5.5% CAGR
- Clinical TrialsUSD 118 bn · 7.0% CAGR
- TelemedicineUSD 103 bn · 13.0% CAGR
- Diabetes DrugsUSD 97.5 bn · 5.0% CAGR
- Generic InjectableUSD 93.3 bn · 6.3% CAGR
- Contract Research OrganizationUSD 91.8 bn · 8.0% CAGR
- Contract Development and Manufacturing OrganizationUSD 140 bn · 8.0% CAGR
- Cardiovascular DevicesUSD 83.8 bn · 7.0% CAGR
← Peptide Receptor Radionuclide Therapy (PRRT) Perimenopause Nutrition Products →